Thanks to its strategic investments, agility, and outstanding management capabilities in a volatile environment, Imexpharm Pharmaceutical Joint Stock Company proudly received Vietnam's 50 Best Performing Companies (TOP50) for 2024 award on December 11, 2024.

The TOP50 rankings, launched annually since 2010 by Nhịp Cầu Đầu Tư magazine in collaboration with Thiên Việt Securities Company, are guided by insights from top business and economic experts at Harvard Business School. The rankings evaluate companies listed on Vietnam’s stock market based on three consecutive years of performance, measured through key indicators: revenue growth, return on equity (ROE), and earnings per share.

This year’s TOP50 highlights the remarkable presence of top-performing Vietnamese enterprises across vital sectors, such as retail, consumer goods, banking, and manufacturing. Imexpharm stood out for its exceptional governance, strategic vision, and resilience amid market fluctuations, achieving impressive results. From 2021 to 2023, Imexpharm recorded average revenue growth of 13%, an ROE of 13%, and investor return rates of 12%.

Leveraging the advantage of EU-GMP certified factory clusters
Imexpharm is among the few listed companies to sustain growth despite ongoing economic uncertainties. This achievement reflects its superior management capabilities, strategic investment in research and development (R&D), and an expanded product portfolio, particularly in specialty drugs, supported by advanced manufacturing capabilities and export-oriented development.
As the pharmaceutical company with the most EU-GMP-certified production lines in Vietnam (12 EU-GMP lines across 3 factory clusters), Imexpharm leads the market in antibiotic production. The company has also achieved remarkable success domestically through both ETC (prescription drugs) and OTC (over-the-counter) channels.
With its EU-GMP-certified facilities, Imexpharm maximizes opportunities from Vietnam’s updated Pharmaceutical Law, which prioritizes domestic production of innovative drugs and high-tech formulations. This aligns with the Drug Administration of Vietnam’s strategy to prioritize locally produced drugs and support export expansion. By 2030, Vietnam aims to achieve $1 billion in pharmaceutical export revenue.
With over 47 years of industry experience, Imexpharm is confident in meeting growing demand for its products, contributing significantly to Vietnam’s National Pharmaceutical Development Strategy. By 2030, domestic production is expected to meet 80% of pharmaceutical demand and account for 70% of the domestic market's total value.
People’s Doctor, Pharmacist Tran Thi Dao, CEO of Imexpharm, stated: "Effective business performance is not just about generating profits; it’s about prioritizing community welfare and sustainable social development. This is the core of Imexpharm’s strategy, as we believe corporate success delivers value to all stakeholders—from employees, investors, and shareholders to the broader community. Imexpharm is committed to being fully prepared in terms of talent, technology, and resources to meet the rising demand for high-quality medicines amidst emerging diseases and global supply chain risks. We aim not only to serve the domestic market but also to integrate into the global supply chain, enhancing Vietnam's pharmaceutical standing."
Strategic R&D Investments
In the first 10 months of 2024, Imexpharm recorded net revenue of VND 1,729 billion, achieving 73% of its annual target. This success is driven by a combination of advanced technology, investments in R&D, environmental responsibility, and sustainable development strategies. These efforts have enabled Imexpharm to pioneer the development of complex formulations such as lyophilized injections, dispersible tablets, and multi-dose powders.
The company is also developing the "Cat Khanh Pharmaceutical Complex" in Dong Thap province. Built to EU-GMP standards over a 25,000 m² area, the project involves a total investment of VND 1,495 billion and is expected to commence operations between December 2028 and Q1 2030. This project forms a critical part of Imexpharm’s strategy to expand production capacity and meet the increasing demand for pharmaceuticals domestically and internationally.
By leveraging high-quality governance and advanced pharmaceutical technologies, Imexpharm not only strengthens its competitive edge against global pharmaceutical corporations but also establishes a solid foundation to triple its revenue by 2030.
Since its inception in 2010, the TOP50 ranking has successfully identified and celebrated Vietnam’s most outstanding companies. Over 13 years, the organizers have witnessed the remarkable growth of local businesses alongside the rapid expansion of the national economy. The 2024 TOP50 ranking will honor companies with exceptional scale, high market capitalization, and robust growth, serving as a source of pride for Vietnam.

Earlier, on December 5, 2024, at the Announcement Ceremony of the VNCG50 Corporate Governance Scorecard at the 7th Annual Forum (AF7), Imexpharm was proudly listed as the Pioneering Enterprise Committed to Improving Corporate Governance in Vietnam - VNCG50.